NCT02617654View on ClinicalTrials.gov

Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Type 1 Diabetes
Interventions
DRUG

Liraglutide

Treatment with liraglutide for 52 weeks

DRUG

Placebo for liraglutide

Placebo for liraglutide. Treatment once daily for 52 weeks

Trial Locations (1)

SE-75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Per-Ola Carlsson

OTHER

NCT02617654 - Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes | Biotech Hunter | Biotech Hunter